scholarly journals Sp1 and chromatin environment are important contributors to the formation of repressive chromatin structures on the transfected human adenine nucleotide translocase-2 promoter

2000 ◽  
Vol 346 (1) ◽  
pp. 93-97 ◽  
Author(s):  
Zdenek HODNY ◽  
Ronggui LI ◽  
Peter BARATH ◽  
B. Dean NELSON

The influence of chromatin on the human adenine nucleotide translocase isoform 2 (ANT2) promoter was investigated in transfected cells treated with the deacetylase inhibitors butyrate and trichostatin A (TSA). Both inhibitors activated the expression of reporter plasmids transfected into HeLa cells, indicating that the promoter was suppressed by hypoacetylated chromatin and activated by hyperacetylation. Inhibitor-dependent activation was traced to the two Sp1-activation elements within the proximal promoter region, indicating that the Sp1 elements are repressed by chromatin structure. Repressive chromatin structures were also formed on the promoter integrated into a stable chromatin environment, as shown by the effects of TSA and butyrate on 14 single-cell-derived NIH3T3 clones bearing the stable integrated ANT2 promoter. Both the basal expression of the luciferase reporter gene and the response to TSA and butyrate varied widely between clones. The range of basal expression (4000-fold) was due partially to variation in the formation of repressive chromatin, since clones with low basal expression were induced by TSA, but those with high basal expression were less effected. These data indicate that chromatin environment surrounding the integrated DNA exerts a strong influence on chromatin-dependent repression of the ANT2 promoter, and that the ability of Sp1 to activate ANT2 expression is compromised in the repressed state.

1996 ◽  
Vol 317 (2) ◽  
pp. 621-625 ◽  
Author(s):  
Michael W. VOICE ◽  
Jonathan R. SECKL ◽  
Christopher R. W. EDWARDS ◽  
Karen E. CHAPMAN

11β-Hydroxysteroid dehydrogenase (11β-HSD) is a key enzyme in glucocorticoid metabolism, catalysing the conversion of active glucocorticoids into their inactive 11-keto metabolites, thus regulating glucocorticoid access to intracellular receptors. The type 1 isoform (11β-HSD 1) (EC 1.1.1.146) is widely distributed, with particularly high levels in liver, where accumulating evidence suggests that it acts as an 11β-reductase, regenerating active glucocorticoids. Investigation of the function and regulation of 11β-HSD 1 in liver has been hampered by the lack of hepatic cell lines which express 11β-HSD 1. Here, we describe 11β-HSD 1 mRNA expression and activity in 2S FAZA cells, a continuously cultured rat liver cell line. In intact 2S FAZA cells 11β-HSD 1 acts predominantly as a reductase, with very low dehydrogenase activity. In 2S FAZA cells 11β-HSD 1 activity and mRNA expression are regulated by hormones, with dexamethasone increasing activity and insulin, forskolin and insulin-like growth factor 1 decreasing it. Transfection of 2S FAZA cells with a luciferase reporter gene driven by the proximal promoter of the rat 11β-HSD 1 gene demonstrates that sequences which can mediate the responses to insulin, dexamethasone and forskolin all lie within 1800 bp of the transcription start site.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1916-1916
Author(s):  
Yosef Dicken ◽  
Amos M. Cohen ◽  
Hanna Bessler ◽  
Daphna Levi-Hirsh ◽  
Ariela Arad ◽  
...  

Abstract hPim-2 is a proto-oncogene that encodes a serine/threonine kinase and inhibits apoptosis by phosphorylation of BAD. We have shown that hPim is upregulated in human non-Hodgkin’s lymphomas (NHL) and in chronic lymphocytic leukemia (B-CLL) and its cellular transcript levels in B-CLL correlates with lymphocyte doubling time. We found no mutations in the promoter region of hPim-2 in B-cells of 30 patients with CLL (~2000 bp upstream). The proximal promoter region of hPim-2 (600 bp) contains two adjacent NF-kB-binding elements, two adjacent Oct-binding elements and an SP1 element by bioinformatic analysis. Studies have recently shown that the transcription factor Oct-2 and the B-cell specific Oct cofactor Bob-1 are overexpressed in certain large B-cell lymphomas, whereas increased expression of Bob-1 has also been observed in T-cell neoplasms. Shift assays (EMSA) analysis, using nuclear extracts from B-CLL cells and various fragments of hPim-2 promoter region used as probes, revealed that complexes containing an Oct elements were consistently heavier in B-CLL extracts compared with control B-cells. Accordingly, Oct-1, Oct-2 and Bob-1 protein levels were significantly higher in B-CLL compared to healthy extracts. Moreover, chromatin immunoprecipitation (Chip) assays confirmed that in-vivo Oct-1+2 and Bob-1 are indeed physically attached to the hPim-2 promoter, and that this interaction is significantly more intensive in B-CLL cells than in control B-cells. Furthermore, we have found in addition that the p52 isoform subunit of NF-kB predominates the interaction with the kB element in the hPim-2 promoter in B-CLL cells, as compared to the p50 isoform observed in control B-cells. To determine whether these interactions are transcriptionaly significant, we fused the luciferase reporter gene to various promoter fragments, and monitored luciferase expression in-vitro after incubation with either B-CLL or normal B-cell extracts. Luciferase expression was consistently higher when Oct element-containing fragment was incubated with B-CLL cell extracts. Together, these results suggest that the upregulation of hPim-2 in B-CLL is due to enhanced expression and transcriptional activity of the Oct-1+2 and Bob-1 complex and that it might synergistically act with the p52 containing NF-kB transcription factor.


2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 183-183
Author(s):  
Junyao Xu ◽  
Qingqi Hong ◽  
Chuanchao He ◽  
Jie Wang

183 Background: SET and MYND Domain-Containing Protein 3 (SMYD3) is frequently overexpressed in hepatocellular carcinoma (HCC) exhibiting increased malignant phenotypes. It has also been known that the hepatitis B virus x protein (HBx) is strongly associated with HCC development and progression. Although overexpression of both proteins is related to HCC, the relationship between the two has not been well studied. Methods: Immunohistochemical staining was used to detect the expression of HBx and SMYD3 in HCC tumor tissues. HBx gene transfection, RNAi, and histone methyltransferase(H3-K4) activity assay were performed to reveal the transcrpitionally activation of HBx on functional SMYD3 gene expression. Chromatin immunoprecipitation (ChIP), Co-immunoprecipitation (Co-IP), Electrophoretic mobility shift assay (EMSA) were applied to investigate the underlying mechanism. Dual-luciferase reporter assay was used to search for the HBx responsive cis-element of SMYD3 gene. Results: Immunohistochemistry identified the positive correlation between HBx and SMYD3 expression in 42 HCC tissues. Up-regulation of HBx on SMYD3 expression was validated through experiments involving overexpression or knock-down of HBx in different HCC cell lines. And up-regulated SMYD3 is functionally active as histone methyltransferase. Next we found that HBx transcriptionally regulated SMYD3 gene expression by interacting with RNA polymerase IIand altering its binding site to a proximal promoter region(SD2) from a distant promoter region(SD6) of SMYD3. Truncated and mutant reporter assays revealed that the cis-element mapped in -178~-203bp in SMYD3 promotor is responsive for HBx-transactivation. And this 25bp cis-element contains a E-box 3 unit, which is a binding site for the transcriptional factor Neurogenic differentiation 1(NeuroD1). EMSA and Chip showed that HBx increased NeuroD1 binding to SMYD3 proximal promotor, however transcient expression of antisense NeuroD1 abolished HBx-induced SMYD3 expression. Conclusions: HBx transcriptionally up-regulates SMYD3 and that this process is mediated by NeuroD1 through binding to the E-box 3 site of SMYD3 promotor.


2008 ◽  
Vol 200 (1) ◽  
pp. 107-116 ◽  
Author(s):  
Katsumori Segawa ◽  
Morihiro Matsuda ◽  
Atsunori Fukuhara ◽  
Kentaro Morita ◽  
Yosuke Okuno ◽  
...  

Adiponectin is exclusively expressed in adipose tissue and secreted from adipocytes, and shows anti-diabetic and anti-atherogenic properties. However, the precise transcriptional mechanism of adiponectin remains elusive. In this study, the 5′ flanking promoter region of human adiponectin gene was analyzed using UCSC genome browser, and a 10 390-bp fragment, containing an evolutionally conserved region among species, was investigated. The luciferase reporter assay using this fragment identified a novel distal enhancer of human adiponectin gene. Promoter constructs with the distal enhancer exhibited high promoter activities in 3T3-L1 mature adipocytes. However, no such activity was observed in other types of cell lines. The distal enhancer is highly conserved, and contains two completely conserved CCAAT boxes. In 3T3-L1 mature adipocytes, deletion or each point mutation of these CCAAT boxes markedly reduced luciferase activity driven by adiponectin promoter. Knockdown of CCAAT/enhancer-binding protein α (CEBPA; also known as C/EBPα) using small interfering RNA diminished adiponectin mRNA expression and luciferase activity driven by adiponectin promoter with the distal enhancer. However, adiponectin promoter with each mutation of two CCAAT boxes in the distal enhancer did not respond to knockdown of CEBPA expression. Furthermore, CEBPA bound to the distal enhancer both in vitro and in vivo. We also identified a proximal promoter region responsible for transcriptional activation by the distal enhancer in human adiponectin gene. Our results indicate that CEBPA plays a pivotal role in the transcription of human adiponectin gene via the distal enhancer and proximal region in its promoter.


2003 ◽  
Vol 17 (3) ◽  
pp. 318-332 ◽  
Author(s):  
Magdalena I. Suszko ◽  
Denise J. Lo ◽  
Hoonkyo Suh ◽  
Sally A. Camper ◽  
Teresa K. Woodruff

Abstract FSH is controlled by a variety of positive and negative stimuli, and the unique FSHβ-subunit is a major target for this regulation. Activin is a key modulator of FSHβ transcription and hormone secretion. The signal transduction pathway leading to FSH expression was previously unknown. Here, we show that the transcription factors Smad3 and Smad4 mediate activin-stimulated activity of the rat FSHβ promoter in a pituitary-derived cell line, LβT2. Cells were transiently transfected with the rat FSHβ promoter fused to a luciferase reporter gene (−338rFSHβ-Luc), and a minimal activin-responsive region was identified. Transfection of Smad3, but not the highly related Smad2, led to a ligand-independent stimulation of the FSHβ promoter activity. As expected, activin caused an additional increase of luciferase expression, which was blocked by cotreatment with follistatin. Although Smad4 alone had no effect on FSHβ transcription, it significantly augmented Smad3 and activin-mediated stimulation of the promoter. A palindromic consensus Smad-binding element in the proximal promoter was found to bind Smad4, and elimination of the region resulted in a loss of activin-mediated FSHβ transcription. The activin signaling pathway is conserved in a number of cells, but FSHβ expression is restricted to gonadotropes. A pituitary-specific transcription factor necessary for activin-dependent induction of the FSHβ promoter has been identified that permits FSHβ expression in nongonadotrope cells. Pitx2 is a member of Pitx subfamily of bicoid-related homeodomain factors that is required for pituitary development and is present in the adult pituitary. This factor was transfected into LβT2 cells, where it caused up-regulation of basal and activin-mediated FSHβ promoter activity. Furthermore, cotransfection of Pitx2c with Smad3 in kidney-derived TSA cells resulted in activin-regulated FSHβ response, suggesting its important role in tissue-restricted regulation of FSHβ by activin. A Pitx2c binding site was identified within the proximal promoter, and elimination of this region also resulted in a loss of activin-regulated FSHβ promoter activity. Taken together, these studies suggest that the regulation of FSHβ is dependent on activin-mediated signaling factors in concert with pituitary-derived nuclear regulatory proteins.


2005 ◽  
Vol 393 (1) ◽  
pp. 321-329 ◽  
Author(s):  
Antonella De Luca ◽  
Paolo Sacchetta ◽  
Carmine Di Ilio ◽  
Bartolo Favaloro

MsrA (methionine sulphoxide reductase A) is an antioxidant repair enzyme that reduces oxidized methionine to methionine. Moreover, the oxidation of methionine residues in proteins is considered to be an important consequence of oxidative damage to cells. To understand mechanisms of human msrA gene expression and regulation, we cloned and characterized the 5′ promoter region of the human msrA gene. Using 5′-RACE (rapid amplification of cDNA ends) analysis of purified mRNA from human cells, we located the transcription initiation site 59 nt upstream of the reference MsrA mRNA sequence, GenBank® accession number BC 054033. The 1.3 kb of sequence located upstream of the first exon of msrA gene was placed upstream of the luciferase reporter gene in a pGL3-Basic vector and transfected into different cell lines. Sequentially smaller fragments of the msrA promoter region were generated by PCR, and expression levels were monitored from these constructs within HEK-293 and MCF7 human cell lines. Analysis of deletion constructs revealed differences in promoter activity in these cell lines. In HEK-293 cells, the promoter activity was constant from the minimal promoter region to the longest fragment obtained. On the other hand, in MCF7 cells we detected a down-regulation in the longest fragment. Mutation of a putative negative regulatory region that is located between −209 and −212 bp (the CCAA box) restored promoter activity in MCF7 cells. The location of the msrA promoter will facilitate analysis of the transcriptional regulation of this gene in a variety of pathological contexts.


2014 ◽  
Vol 115 (suppl_1) ◽  
Author(s):  
Jie Wang ◽  
Yan Jin ◽  
Peter A Cattini

Doxorubicin (DOX) is a widely used and effective anti-cancer drug, but it is also cardiotoxic, which can lead to heart failure, and so strategies are needed to protect the heart. Fibroblast growth factor 16 (FGF-16) is preferentially expressed and released from cardiomyocytes after birth. Evidence suggests that FGF-16 decreases the risk of heart damage and limits the negative effects of heart remodeling (hypertrophy and fibrosis) after injury in vivo. Exogenous addition of FGF-16 also increased resistance to the loss of contractility in an isolated heart model of acute DOX-induced injury. Thus, how endogenous FGF-16 production and by extension function is affected by DOX treatment is of interest. The FGF-16 gene is highly conserved between human and murine species. Alignment of sequences indicates a conserved Nkx2.5 binding site in the proximal promoter region that is associated with a previously characterized TATA box. Nkx2.5 is an important factor in vertebrate heart development and congenital disease. Furthermore, Nkx2.5 RNA levels are decreased with DOX treatment. Thus, the possibility that DOX negatively affects FGF-16, perhaps through an effect on Nkx2.5 levels or binding, was investigated. Neonatal rat cardiomyocytes were treated with DOX, and FGF-16 RNA levels decreased 75% within 6 hours as assessed by qPCR. Inhibition of transcription with actinomycinD had no effect on the DOX-induced decrease in FGF-16 RNA levels. Further support for an effect of DOX on FGF-16 transcription was obtained by transfection of cardiomyocytes with a hybrid 747 bp mouse FGF-16 promoter/luciferase reporter gene that was treated with DOX; a significant decrease in luciferase activity was observed. Electrophoretic mobility shift and chromatin immunoprecipitation assays suggest reduced Nkx2.5 protein-DNA interaction with this site after DOX treatment in vitro and in situ, respectively. These data indicate that DOX decreases FGF-16 RNA expression and this correlates with a decrease in Nkx2.5 levels and association with the proximal promoter region. A direct effect of Nkx2.5 on FGF-16 promoter activity awaits further testing. Thus, a decrease or loss of FGF-16 synthesis might contribute to the DOX-induced damage and/or response to injury.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3386-3386
Author(s):  
Elisa Bianchi ◽  
Paola Guglielmelli ◽  
Lorenzo Tozzi ◽  
Costanza Bogani ◽  
Simona Salati ◽  
...  

Abstract Abstract 3386 Deregulated expression of miRNAs is associated with neoplasia. We recently showed that miR-16-2 is overexpressed in CD34(+) cells of patients with polycythemia vera (PV) versus their normal counterparts and that deregulation of miR-16-2 contributes, in a way independent of JAK/STAT pathway activation, to the abnormal expansion of the erythroid lineage characterizing PV. In fact, forced expression of miR-16 in normal CD34+ cells stimulated erythroid maturation while exposure of PV CD34(+) cells to antagomirs against pre-miR-16-2 reduced erythroid colonies. Moreover, erythroid fate was impaired in mice injected with a miR-16 antagomir, indicating a role of miR-16 in normal erythropoiesis. Collectively these data identified miR-16-2 as a positive regulator of the erythropoiesis and linked the abnormal expansion toward the erythroid lineage to the overexpression of miR-16-2 in PV patients (Guglielmelli P, Blood, 117:6923–6927, 2011). However, the mechanisms underlying miR-16-2 overexpression are still unknown. In this project we aim to identify the transcription factors regulating miR-16-2 expression in normal and PV erythropoiesis. miR-16-2 is an intronic miRNA located within the SMC4 (Structural Maintenance of Chromosome 4) gene on chromosome 3. A functionally defined promoter of miR-16 has not been characterized yet. Therefore, (1) based on data from genome-wide studies of H3K4me3, H3K9/14Ac, RNA pol II-enrichment and nucleosome positioning identifying a RNA pol II-enriched region overlapping the SMC4 promoter for miR16-2 expression control and (2) based on the evidence of a correlation between the expression levels of this intronic miRNA and those of its host gene SMC4, we focused our attention on the transcriptional regulators of SMC4 gene. We screened the SMC4 gene promoter region in order to identify putative binding sites for transcription factors already known to be involved in erythroid differentiation, such as c-myb, KLF1 and GATA1. Next, we cloned the SMC4 promoter region between ∼20 bp downstream and 1200 bp upstream the Transcription Start Site into the pXP1 plasmid, upstream to the promoterless firefly luciferase reporter gene. HEK293T cells were transfected with the pXP1 vector carrying the Luciferase reporter gene under the SMC4 promoter control and increasing amounts of plasmid coding for either c-myb or KLF1. Luciferase activity measurements were done in duplicate and signals were normalized for transfection efficiency to the internal Renilla control. At least 3 independent experiments were performed for each of the transcription factors tested. Our data demonstrated that increasing levels of c-myb protein expression are able to transactivate SMC4 promoter-driven luciferase expression. In fact, increasing amounts of the c-myb-coding plasmid determined a dose-dependent increase in SMC4 promoter-driven luciferase activity (735+/−196, 995+/−286 and 1759+/−474 for 100, 200 and 400ng of c-myb-coding plasmid respectively, versus 590+/−190 for the empty plasmid control; average+/−SD values). Therefore, the c-myb-driven SMC4 promoter transactivation trend identified (P<0.01 in myb-coding versus empty vector transfected samples) points out the potential involvement of c-myb in SMC4/miR-16-2 upregulation during normal and/or pathologic erythroid differentiation. On the contrary, increasing levels of KLF1 expression failed to affect SMC4 promoter-driven luciferase gene expression, suggesting that a role for KLF1 in this process could be ruled out. Further experiments will elucidate the role of GATA1 in this process. In conclusion, our data demonstrated that c-myb is able to transactivate SMC4/miR16-2 expression, by shedding for the first time some light on the molecular players involved in normal and PV erythropoiesis. Despite the overwhelming body of studies demonstrating the key role of c-myb in the erythropoiesis, little is known on the molecular mechanisms of c-myb-driven erythroid differentiation. We recently gained insights in this process by demonstrating that c-myb supports erythropoiesis by transactivating KLF1 and LMO2 expression (Bianchi E, Blood, 116:e99–110, 2010). The present data suggest SMC4/miR16 transactivation as a new pathway through which c-myb affects the erythroid differentiation. However, further studies need to be performed to more deeply unravel this mechanism and its relevance in normal and PV erythropoiesis. Disclosures: No relevant conflicts of interest to declare.


2002 ◽  
Vol 283 (1) ◽  
pp. E50-E57 ◽  
Author(s):  
Quan He ◽  
Mariela Mendez ◽  
Margot C. LaPointe

Brain natriuretic peptide (BNP) is a cardiac hormone constitutively expressed in the adult heart. We previously showed that the human BNP (hBNP) proximal promoter region from −127 to −40 confers myocyte-specific expression. The proximal hBNP promoter contains several putative cis elements. Here we tested whether the proximal GATA element plays a role in basal and inducible regulation of the hBNP promoter. The hBNP promoter was coupled to a luciferase reporter gene (1818hBNPLuc) and transferred into neonatal ventricular myocytes (NVM), and luciferase activity was measured as an index of hBNP promoter activity. Mutation of the putative GATA element at −85 of the hBNP promoter [1818(mGATA)hBNPLuc] reduced activity by 97%. To study transactivation of the hBNP promoter, we co-transfected 1818hBNPLuc with the GATA-4 expression vector. GATA-4 activated 1818hBNPLuc, and this effect was eliminated by mutation of the proximal GATA element. Electrophoretic mobility shift assay showed that an oligonucleotide containing the hBNP GATA motif bound to cardiomyocyte nuclear protein, which was competed for by a consensus GATA oligonucleotide but not a mutated hBNP GATA element. The β-adrenergic agonist isoproterenol and its second messenger cAMP stimulated hBNP promoter activity and binding of nuclear protein to the proximal GATA element. Thus the GATA element in the proximal hBNP promoter is involved in both basal and inducible transcriptional regulation in cardiac myocytes.


Sign in / Sign up

Export Citation Format

Share Document